



Complete Summary

GUIDELINE TITLE

Care of the patient with open angle glaucoma. 2nd edition.

BIBLIOGRAPHIC SOURCE(S)

American Optometric Association. Care of the patient with open angle glaucoma. 2nd ed. St. Louis (MO): American Optometric Association; 2002 Aug 17. 104 p. [589 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously published version: Care of the patient with open angle glaucoma. St. Louis (MO): American Optometric Association; 1995. 90 p.

According to the guideline developer, this guideline has been reviewed on a biannual basis and is considered to be current. This review process involves updated literature searches of electronic databases and expert panel review of new evidence that has emerged since the original publication date.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
CONTRAINDICATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

- Primary open angle glaucoma
- Secondary open angle glaucoma
 - Pigmentary glaucoma

- Pseudoexfoliation glaucoma

GUIDELINE CATEGORY

Diagnosis
Evaluation
Management
Treatment

CLINICAL SPECIALTY

Optometry

INTENDED USERS

Health Plans
Optometrists

GUIDELINE OBJECTIVE(S)

- To identify patients at risk of developing open angle glaucoma
- To accurately diagnose open angle glaucoma
- To improve the quality of care rendered to patients with open angle glaucoma
- To minimize the damaging effects of open angle glaucoma
- To preserve the gains obtained through treatment
- To inform and educate patients and other health care practitioners about the visual complications, risk factors, treatment options, and adverse reactions to treatments associated with open angle glaucoma

TARGET POPULATION

Patients with suspected or diagnosed open angle glaucoma

INTERVENTIONS AND PRACTICES CONSIDERED

Diagnosis/Evaluation

1. Patient history
2. Ocular examination
3. Supplemental testing

Management/Treatment

1. Medical (Pharmaceutical)
 - Adrenergic antagonists: beta-blockers
 - Prostaglandin analogs
 - Alpha-2 adrenergic agonist
 - Topical carbonic anhydrase inhibitor
 - Adrenergic agonists: epinephrine compounds
 - Miotics
 - Oral carbonic anhydrase inhibitors

2. Laser therapy
3. Surgery
 - Filtering procedures
 - Cyclodestructive procedures
4. Alternative strategies
5. Patient education

MAJOR OUTCOMES CONSIDERED

- Efficacy of treatment
- Adverse effects of treatment/medications

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The guideline developer performed literature searches using the National Library of Medicine's Medline database and the VisionNet database.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Expert Consensus (Committee)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Review
Review of Published Meta-Analyses

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not applicable

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Internal Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

The Reference Guide for Clinicians was reviewed by the American Optometric Association (AOA) Clinical Guidelines Coordinating Committee and approved by the AOA Board of Trustees.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Initial Glaucoma Evaluation

The initial glaucoma evaluation may include the tests and procedures of a comprehensive adult eye and vision examination in addition to some procedures specific to the differential diagnosis of glaucoma. Baseline data are established for key clinical parameters that must be evaluated longitudinally in the proper management of glaucoma. Potential components of an initial glaucoma evaluation (discussed in detail in the original guideline document) include:

1. **Patient history**
 - Ocular and systemic risk factors and medical history
2. **Visual acuity**
 - Corrected and uncorrected visual acuity
3. **Pupil assessment**
 - Relative afferent pupillary defect
4. **Biomicroscopy**
 - Evaluation of anterior and posterior ocular segment
5. **Applanation tonometry**
 - Diurnal variability
 - Symmetry
6. **Gonioscopy**
 - Open or closed angle
 - Primary or secondary glaucoma
7. **Assessment of optic nerve**
 - Stereoscopic evaluation through a dilated pupil
 - Tomography
8. **Assessment of nerve fiber layer**
 - Stereoscopic evaluation through a dilated pupil

- Evaluation with red-free illumination
- Confocal scanning laser polarimetry, optical coherence tomography, confocal scanning laser ophthalmoscopy

9. Assessment of peripapillary area (PPA)

10. Fundus stereo photography

- Photodocumentation of optic nerve and nerve fiber layer

11. Visual Fields

- Standard automated perimetry
- Frequency doubling perimetry
- Short wavelength automated perimetry

Follow-up Glaucoma Evaluation

Individuals with one or more risk factors, who have higher probabilities of developing primary open angle glaucoma (POAG), need more frequent evaluation to rule out the presence of the earliest clinical signs of glaucoma. This evaluation should be done at least yearly in the absence of complicating factors, but perhaps more often, depending on the person's relative risk of developing glaucoma.

Follow-up evaluation of the patient with diagnosed open angle glaucoma (OAG) is similar to the procedure used to make the initial diagnosis of the disease and may include, but is not limited to, the following assessments (further discussed in the original guideline document):

- Patient history
- Visual acuity
- Blood pressure and pulse
- Biomicroscopy
- Tonometry
- Gonioscopy
- Optic nerve assessment
- Nerve fiber layer assessment
- Fundus photography
- Automated perimetry
- Supplemental testing

Available Treatment Options

Traditionally glaucoma treatment has begun with pharmacological intervention, proceeding to laser therapy and surgery, when necessary. This approach was designed to maximize the benefit of the treatment, while minimizing the risk to the patient. Recently, this method has been challenged as less effective than other sequences of therapy. Many glaucoma patients may require all three treatment options. These options should be available because glaucoma is a chronic, progressive disease with no known cure.

In the choice of a specific form of treatment or the decision to alter or provide additional therapy, the risk or benefit to the patient must be the overriding consideration. All forms of treatment for glaucoma have potential side effects or complications. The possible impact of the treatment socially, psychologically, financially, and from a convenience standpoint must be evaluated.

The following three levels of treatment are described in greater detail in the guideline document:

Medical (Pharmaceutical)

The treatment of open angle glaucoma (OAG) includes the use of orally administered or topical agents that enhance aqueous outflow or reduce aqueous production or both. Pharmacological management of OAG includes:

- Cholinergic agonists – miotics (pilocarpine – solution, gel, or membrane-bound wafer; carbachol)
- Adrenergic agonists (nonselective [epinephrine, dipivefrin]; selective [apraclonidine, brimonidine])
- Beta-adrenergic blocking agents (nonselective [carteolol, levobunolol, metipranolol, timolol] selective [betaxolol])
- Carbonic anhydrase inhibitors (systemic –oral [acetazolamide – injection or sustained release, dichlorphenamide, methazolamide], topical [dorzolamide, brinzolamide])
- Prostaglandin analogs (bimatoprost, latanoprost, travoprost, unoprostone isopropyl)
- Combination medications

Laser therapy

The second level of primary open angle glaucoma (POAG) involves the use of systemic medication or laser procedures. As an alternative to drug therapy, argon laser trabeculoplasty (ALT) is a common treatment after topical medication for POAG.

Surgery

Surgical intervention, the third level of treatment for POAG, is required in many moderate or advanced glaucoma patients, to lower the intraocular pressure (IOP) into the target range, especially in normal tension glaucoma (NTG) or eyes resistant to other forms of therapy.

Filtration surgical procedures create alternative pathways for the outflow of aqueous. Among various filtering procedures used to lower IOP are thermal sclerostomy, posterior or anterior lip sclerectomy, trephination, and trabeculectomy. Cyclodestructive procedures, which damage the ciliary body and thereby decrease aqueous production, are less commonly used, being reserved for the most advanced stages of the disease.

Patient Education

The proper management of glaucoma requires full compliance by the patient. Patient education regarding the benefits and risks of the treatment and proper use of medications is critical to ensure maximum compliance. Continual reinforcement of the seriousness of the disease and the importance of following the therapy regimen is essential.

Prognosis and Follow-Up

Once treatment for glaucoma has been initiated, follow-up examinations are required to monitor: stability of the intraocular pressure (IOP), optic nerve (ON), visual field (VF), and **peripapillary area** (PPA); patient compliance with the therapy; the presence of side effects associated with the treatment; and the effectiveness of patient education. Follow-up also provides an opportunity to reconfirm the diagnosis. Determining whether the disease is progressing may be clinically challenging, due to the difficulty, in some patients, of distinguishing subtle structural or functional changes representing normal fluctuation from changes caused by progressive glaucomatous damage.

The frequency of follow-up evaluations of a glaucoma patient under active treatment depends on the level of intraocular pressure and the stability and severity of the disease. The following table summarizes the frequency and composition of evaluation and management visits for open angle glaucoma.

Frequency and Composition of Evaluation and Management Visits for Open Angle Glaucoma

Type of Patient	Frequency of Examination	Tonometry	Gonioscopy	Optic Nerve (ON)/Nerve Fiber Layer (NFL) Assessment	Stereoscopic ON, NFL, and Peripapillary Area (PPA) Documentation Confocal scanning laser imaging (CSLI)**	Perimetry
New glaucoma patient or new glaucoma suspect	Weekly or biweekly to achieve target pressure	Multiple readings may be necessary to establish baseline	Standard classification and drawing an initial visit	Dilate; optic nerve drawing at initial visit	As part of initial glaucoma evaluation	Repeat established baseline
Glaucoma suspect	6 to 12 months, depending on level of risk	Multiple readings may be necessary to establish baseline	Annual	Dilate every other visit	Every 2 years; CSLI Annual*	Annual
Stable - mild stage	4 to 6 months	Every visit	Annual	Dilate every other visit	Annual	Annual
Stable - moderate stage	2 to 4 months	Every visit	Annual	Dilate every other visit	Annual	6 to -12 months depending on prior data

Type of Patient	Frequency of Examination	Tonometry	Gonioscopy	Optic Nerve (ON)/Nerve Fiber Layer (NFL) Assessment	Stereoscopic ON, NFL, and Peripapillary Area (PPA) Documentation Confocal scanning laser imaging (CSLI)**	Perimetry
Stable - severe stage	1 to 3 months	Every visit	6 months	Dilate every other visit	Annual; CSLI?*	4 to 8 months depending on prior data
Unstable - IOP poorly controlled; ON or VF progressing	Weekly or biweekly until stability is established	Every visit	Initial visit and each time other clinical findings warrant a reassessment	Dilate at initial visit and each time other clinical findings warrant reassessment	Annual or each time ON or NFL changes	4 to 6 weeks or as needed to establish new baseline
Recently established stability	1 to 3 months	Every visit; re-establish baseline	Depends on severity of the glaucoma	Dilate every interim visit	Annual or each time ON or NFL changes	Depends on severity of the disease

*Confocal scanning laser imaging (CSLI) is recommended once annually in glaucoma suspect patients and those with mild to moderate disease who can respond to standard testing. CSLI may be performed up to 2 times per year for patients in whom visual fields or tonometry cannot be assessed or in patients with unstable borderline control and other glaucoma risk factors. CSLI may not be useful for monitoring stable-severe or end-stage disease.

**Threshold automated perimetry is recommended.

CLINICAL ALGORITHM(S)

An algorithm is provided for Optometric Management of the Patient with Primary Open Angle Glaucoma.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

The effectiveness of the treatment of primary open angle glaucoma (POAG) depends on the specific modality and varies significantly between studies. The majority of POAG patients with maximally tolerated medical therapy will show progression of the disease within 10 years of initial treatment. This rate of progression can be reduced if the intraocular pressure (IOP) is maintained at about 16 to 17 mm Hg. In only about one-half of cases is glaucoma adequately controlled 5 years after argon laser trabeculoplasty (ALT), no more than one-third after 10 years. Filtration surgery in a previously unoperated eye with POAG has a high initial success rate. Progression of visual field (VF) loss following filtering surgery can be minimized when the IOP is maintained at about 15 mm Hg. Target IOPs for maintaining stability during the treatment of POAG need to be adjusted on an individual basis, depending on patient age, cumulative risk for progression of the disease, and severity of the glaucoma.

Subgroups Most Likely to Benefit

Risk Factors for the Development of Glaucoma

- *Age*: The prevalence of glaucoma is 4 to 10 times higher in the older age groups than in persons in their forties.
- *Race*: African Americans develop primary open angle glaucoma earlier, do not respond as well to treatment, require surgery at a higher rate and have a higher prevalence of blindness from glaucoma than Caucasians.
- *Genetic factors*: Close relatives of persons with primary open angle glaucoma have a prevalence of the disease 3 to 6 times greater than that of the general public, and first-degree relatives have a 3 to 5 times higher incidence of the disease.
- *Ocular*: Intraocular pressure has a strong and direct relationship with the prevalence and long-term risk for glaucoma.

POTENTIAL HARMS

Adverse Effects of Medical Treatment (Pharmaceuticals)

Pharmaceutical agents	Adverse reactions	
	Ocular	Systemic
Pilocarpine	Stinging, irritation Ciliary spasms (myopia) Miosis (vision) Pupillary block Retinal detachment	Headache, pain Sweating Vomiting/diarrhea Salivation Bradycardia Arrhythmia Dyspnea

Pharmaceutical agents	Adverse reactions	
	Ocular	Systemic
Epinephrine ¹	Stinging, burning Mydriasis Allergic sensitivity Pigment deposits Cystoid macular edema Increased intraocular pressure (IOP)	Increased blood pressure Increased heart rate Severe headaches Anxiety
Alpha-2 agonists	Allergic sensitivity ² Minimal mydriasis ² Lid retraction ² Conjunctival vasoconstriction ² Stinging, burning Foreign body sensation Hyperemia Conjunctival follicles	Gastrointestinal discomfort Taste abnormalities Headache Fatigue/drowsiness Oral dryness
Topical beta-blockers	Stinging, burning Superficial punctate keratitis Allergic sensitivity Decreased corneal sensitivity Uveitis ⁴	Dyspnea ³ Bronchiole constriction ³ Decreased heart rate ³ Arrhythmias ³ Decreased blood pressure Depression, confusion Gastrointestinal discomfort Impotence Sleep disturbance Serum lipoprotein alterations Masking symptoms of diabetes mellitus and hyperthyroidism
Oral carbonic anhydrase inhibitors	None	Malaise Depression, confusion Metallic taste Anorexia Diarrhea Paresthesias Kidney stones Metabolic acidosis Blood dyscrasias
Topical carbonic anhydrase inhibitors	Stinging/burning Allergic sensitivity Blurred vision Superficial punctate keratitis	Altered taste

Pharmaceutical agents	Adverse reactions	
	Ocular	Systemic
Prostaglandin analogs	Corneal edema	
	Blurred vision	Headaches
	Stinging, burning	Upper respiratory tract symptoms
	Hyperemia	
	Foreign body sensation	
	Itching	
	Increased iris pigmentation ⁵	
	Eyelash changes	
	Punctate epithelial keratitis	
	Cystoid macular edema	
	Iritis	
	Herpes simplex keratitis	

¹ Adverse ocular reactions and contraindications are less with dipivefrin than with epinephrine

² Adverse ocular reactions are less common with brimonidine

³ May be less severe with betaxolol

⁴ Metipranolol

⁵ Only one reported change in iris coloration with unoprostone isopropyl

Complications of Laser therapy

Possible complications of argon laser trabeculoplasty (ALT) include an increase in intraocular pressure within hours of the procedure and inflammation, which may lead to the formation of peripheral anterior synechiae.

Complications of Surgery

Short-term complications from filtering surgery can include the development of shallow anterior chambers, hypotony, choroidal detachment, uveitis, hyphema, suprachoroidal hemorrhages, and loss of a remaining small island of central vision. Long-term complications can include corneal edema, infection, leaking or failure from fibrosis of the subconjunctival bleb, cataract formation, and endophthalmitis.

CONTRAINDICATIONS

CONTRAINDICATIONS

Contraindications to Pharmaceutical Agents

Contraindications	
Ocular	Systemic

Contraindications

	Ocular	Systemic
Pilocarpine	History of retinal detachment Severe myopia Cataracts Inflammation/infection Aphakia/pseudophakia	Asthma Ulcers Bladder dysfunction Parkinson's disease
Epinephrine	Aphakia/pseudophakia Narrow angles	Systemic hypertension Heart disease Hyperthyroidism Diabetes mellitus Certain medications
Alpha-2 agonists	None	None
Topical beta-blockers	Narrow angles	Chronic obstructive pulmonary disease (COPD) Systemic hypotension Bradycardia Diabetes mellitus Myasthenia gravis Certain medications
Oral carbonic anhydrase inhibitors	None	History of kidney stones Liver disease Sulfonamide allergy Cardiac disease Addison's disease Renal disease Severe COPD
Topical carbonic anhydrase inhibitors	Corneal endothelium compromise	Sulfonamide allergy
Prostaglandin analogs	History of uveitis, cystoid macular edema, herpes simplex, keratitis, complicated cataract surgery	None

Contraindication to Laser Therapy

The use of argon laser trabeculoplasty (ALT) is contraindicated in patients with corneal edema or opacities that prevent a clear view of the anterior chamber angle, in those who have certain forms of secondary glaucoma, and in situations, where a large decrease in intraocular pressure is required.

Contraindications to Surgery

Filtering surgery is contraindicated in eyes that are already blind and in patients with severe systemic medical problems.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

- Clinicians should not rely on this Clinical Guideline alone for patient care and management. Please refer to the references and other sources listed in the original guideline for a more detailed analysis and discussion of research and patient care information.
- The components of patient care described in this guideline are not intended to be all-inclusive. Professional judgment and individual patient symptoms and findings may have significant impact on the nature, extent, and course of services provided. Some components of care may be delegated.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

IMPLEMENTATION TOOLS

Clinical Algorithm

For information about [availability](#), see the "Availability of Companion Documents" and "Patient Resources" fields below.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

American Optometric Association. Care of the patient with open angle glaucoma. 2nd ed. St. Louis (MO): American Optometric Association; 2002 Aug 17. 104 p. [589 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1995 (revised 2002 Aug 17; reviewed 2007)

GUIDELINE DEVELOPER(S)

American Optometric Association - Professional Association

SOURCE(S) OF FUNDING

Funding was provided by the Vision Service Plan (Rancho Cordova, California) and its subsidiary Altair Eyewear (Rancho Cordova, California)

GUIDELINE COMMITTEE

American Optometric Association Consensus Panel on Care of the Patient with Open Angle Glaucoma

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Members: Thomas L. Lewis, OD, PhD (Author); Howard S. Barnebey, MD (1st Edition); Jimmy D. Bartlett, OD; Allen J. Blume, OD; Murray Fingeret, OD; Peter A. Lalle, OD; Daryl F. Mann, OD

Assisted by: Sigrid Mueller, OD; Kelly S. Shintani, OD

AOA Clinical Guidelines Coordinating Committee Members: John C. Townsend, OD, *Chair* (2nd Edition); John F. Amos, OD, MS (1st and 2nd Editions); Barry Barresi, OD, PhD (1st Edition); Kerry L. Beebe, OD (1st Edition); Jerry Cavallerano, OD, PhD (1st Edition); John Lahr, OD (1st Edition); W. Howard McAlister, OD, MPH (2nd Edition); Stephen C. Miller, OD (2nd Edition); David Mills, OD (1st Edition)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously published version: Care of the patient with open angle glaucoma. St. Louis (MO): American Optometric Association; 1995. 90 p.

According to the guideline developer, this guideline has been reviewed on a biannual basis and is considered to be current. This review process involves updated literature searches of electronic databases and expert panel review of new evidence that has emerged since the original publication date.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the [American Optometric Association Web site](#).

Print copies: Available from the American Optometric Association, 243 N. Lindbergh Blvd., St. Louis, MO 63141-7881.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on December 2, 1999. The information was verified by the guideline developer as of January 31, 2000. This summary was updated by ECRI on April 16, 2004. The information was verified by the guideline developer on May 10, 2004.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions as follows:

Copyright to the original guideline is owned by the American Optometric Association (AOA). NGC users are free to download a single copy for personal use. Reproduction without permission of the AOA is prohibited. Permission requests should be directed to Jeffrey L. Weaver, O.D., Director, Clinical Care Group, American Optometric Association, 243 N. Lindbergh Blvd., St. Louis, MO 63141; (314) 991-4100, ext. 244; fax: (314) 991-4101; e-mail: JLWeaver@AOA.org.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 10/13/2008

